Abstract
The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.
Keywords: ADCC; COVID-19; Coronavirus; SARS-CoV-2; Spike glycoproteins; delayed mRNA vaccine regimen; humoral responses; neutralization; variants of concern; variants of interest.
【저자키워드】 COVID-19, SARS-CoV-2, coronavirus, neutralization, variants of concern, spike glycoproteins, ADCC, humoral responses, delayed mRNA vaccine regimen, variants of interest., 【초록키워드】 Efficacy, vaccine doses, spike, mRNA vaccine, neutralization, variant, variants, vaccine dose, BNT162b2, Cohort, Humoral response, spike glycoproteins, response, D614G, variants of interest, ADCC, humoral responses, BNT162b2 mRNA, BNT162b2 mRNA vaccine, dose, humoral, regimen, health authorities, second dose, infected individual, infected individuals, naïve individuals, individual, doses, vaccinees, while, vaccine administration, naïve vaccinees, Administered, robust, significantly increased, IMPROVE, greater, analyzed, significantly, include, receiving, question, elicited, public health authority, raising, 【제목키워드】 spike, humoral immune response, BNT162b2 mRNA vaccination, dose, Strong,